M
Mary L. Disis
Researcher at Fred Hutchinson Cancer Research Center
Publications - 402
Citations - 24320
Mary L. Disis is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Immune system & Antigen. The author has an hindex of 71, co-authored 361 publications receiving 21491 citations. Previous affiliations of Mary L. Disis include American Medical Association & University of Nebraska Medical Center.
Papers
More filters
Journal ArticleDOI
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J. Curiel,George Coukos,Linhua Zou,Xavier Alvarez,Pui Cheng,Peter Mottram,Melina Evdemon-Hogan,Jose R. Conejo-Garcia,Lin Zhang,Matthew E. Burow,Yun Zhu,Shuang Wei,Ilona Kryczek,Ben Daniel,Alan N. Gordon,Leann Myers,Andrew A. Lackner,Mary L. Disis,Keith L. Knutson,Lieping Chen,Weiping Zou +20 more
TL;DR: It is shown, in detailed studies of CD4+CD25+FOXP3+ Treg cells in 104 individuals affected with ovarian carcinoma, that human tumor T Reg cells suppress tumor-specific T cell immunity and contribute to growth of human tumors in vivo.
Journal ArticleDOI
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
Keith L. Knutson,Mary L. Disis +1 more
TL;DR: Early clinical trials have shown that focus on the Th effector arm of the immune system can result in significant levels of both antigen-specific Th cells and CTL, the generation of long lasting immunity, and a Th1 phenotype resulting in the development of epitope spreading.
Journal ArticleDOI
Toxicities of Immunotherapy for the Practitioner
TL;DR: The toxicities that are unique to immunotherapies are summarized, emphasizing the need to familiarize the oncology practitioner with the spectrum of adverse events seen with newly approved and emerging modalities.
Journal Article
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.
Mary L. Disis,Emanuel Calenoff,Graham McLaughlin,Ann E. Murphy,Wei Chen,Bernd Groner,Margit Jeschke,Nick Lydon,E. McGlynn,Robert B. Livingston,Roger E. Moe,Martin A. Cheever +11 more
TL;DR: The current data support the notion that HER-2/neu-specific immunity might be used in therapy without destroying normal tissue but also raises questions as to the role of existent immunity in immune surveillance and cancer progression.
Journal ArticleDOI
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Sasha E. Stanton,Mary L. Disis +1 more
TL;DR: Tumor infiltrating lymphocytes (TIL) play an essential role in mediating response to chemotherapy and improving clinical outcomes in all subtypes of breast cancer, yet the presence of TILs has not shown the same survival benefit.